DR-313 Oncogenic pathways and their interaction with the immune system: prediction for response to combined therapies

We hypothesize that (in)activation of specific oncogenic pathways modulates the immune response to the tumor and initiates oncogenic pathway-specific immune escapes in lung cancer. Future of immuno-oncology (IO), therefore, lies in personalized therapies of small molecule inhibitors and specific immunotherapies. In this research, we will unravel the interaction of oncogenic pathways and specific immune responses using publicly available sequencing data of lung adenocarcinoma and squamous cell carcinoma. Subsequently, we will validate the findings in cell lines and in biopsy material.

Teodora Radonic, VU Medical Center, Amsterdam UMC, the Netherlands